Detalhe da pesquisa
1.
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
Euro Surveill
; 29(6)2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38333937